JK

Jeffrey Karp

Founder of Akita Biosciences

Boston, Massachusetts

Overview 

Jeffrey Karp is a distinguished author of "LIT: Life Ignition Tools" and currently holds the position of Professor at Harvard Medical School, Principal Faculty at the Harvard Stem Cell Institute, and Affiliate Faculty at MIT and The Broad Institute. With a background in biomaterials and regenerative medicine, he has co-founded multiple successful ventures like Akita Biosciences and Alivio Therapeutics, and has made significant contributions to the field through his research and advisory roles at institutions like Brigham & Women's Hospital and Frequency Therapeutics.

Work Experience 

  • Contributing Author

    2024 - Current

Psychology Today is a publishing company that publishes news, articles, and magazines about wellness.

  • Co-Founder

    2022

Akita Biosciences is a biotech organization pioneering novel intranasal therapies that help people live healthy and vibrant lives.

  • Author of LIT - Life Ignition Tools (Harper Collins - William Morrow Imprint)

    2019

    ✨Please consider pre-ordering at your favorite retailer: http://bit.ly/3OUGWCO 🙏🏻 Life Ignition Tools are a set of holistic tools for living that emerged out of necessity from my own life. As a child struggling with undiagnosed ADHD and learning differences, I learned how to essentially take control of my brain’s neuroplasticity (neuroplasticity reflects our intrinsic link to nature - it's how our brain adapt and evolve in response to our environment and our thoughts, emotions, and actions) – it was a lifesaver! It gave me the ability to laser focus, enter the flow state on demand, improve memory, emotionally regulate, and more. Named LIT, these tools, inspired by nature and backed by science, empower anyone to lead a life rich in creativity, connection, and purpose. LIT got me through spectacular setbacks along the way (including being rejected from medical school, freezing during a TED talk, struggling to connect meaningfully with others, and countless other challenges) and to where I am today. And the thing is - anyone can do this and start living a life full of creativity, and connection and purpose. Additionally, "LIT" features insights from 40 interviewees, including Nobel laureates, Olympic medalists, social justice leaders, an indigenous leader, celebrated artists, and various scientists and inventors. They share their experiences disengaging from life on autopilot by activating the brain's inherent power to undergo transformative change.

HarperCollins is an English language publisher that offers a range of Bibles, atlases, dictionaries, and reissued classics.

  • Co-Founder

    2019

Corner Therapeutics is a biotechnology research company that specializes in the immunotherapy paradigm.

Raised $54,000,000.00 from Sandia Holdings, Ziff Capital Partners and Tanis ventures.

  • Professor of Anesthesia

    2007

  • Associate Professor

    2012 - 2018

  • Co-Director of Regenerative Therapeutics

    2010 - 2013

  • Assistant Professor

    2009 - 2012

  • Instructor of Medicine

    2007 - 2009

  • Co-Founder

    2015

  • Editorial Advisory Board Member

    2015

    Honored to serve on the 2015,2016 and 2017 TEDMED Editorial Advisory Board for curating the stage program’s themes, topics, speakers and performers.

TEDMED is a global community that creates and shares stories in health and medicine that inform, inspire, engage, and provoke action.

  • Co-Founder, Scientific Advisory Board Member, and Board Observer

    2016

  • Associate Member

    2015

  • Co-Founder, Member of the Regenerative Medicine Advisory Board

    2014

    Frequency Therapeutics, is a biotechnology company at the forefront of translating ground breaking discoveries in the area of cell programming, an approach recognized with the 2012 Nobel Prize, to patients. Frequency has solved a key bottleneck in bringing stem cell programming to patients - namely by harnessing rapidly translatable small molecule combinations that selectively target stem cells in the body. The company is advancing a robust pipeline of small molecule combinations with novel mechanisms of action for hearing loss, gut diseases (including Crohn's disease and ulcerative colitis), diabetes, and ophthalmological diseases.

Articles About Jeffrey

Relevant Websites